Cargando…

The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review

In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sclerosis, including beta interferon, glatiramer acetate, fingolimod, teriflunomide, dimethyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biolato, Marco, Bianco, Assunta, Lucchini, Matteo, Gasbarrini, Antonio, Mirabella, Massimiliano, Grieco, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354931/ https://www.ncbi.nlm.nih.gov/pubmed/34319570 http://dx.doi.org/10.1007/s40263-021-00842-9

Ejemplares similares

Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients
por: Nociti, Viviana, et al.
Publicado: (2018)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2022)

Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach
por: Biolato, Marco, et al.
Publicado: (2017)

Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review
por: Carlomagno, Vincenzo, et al.
Publicado: (2023)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
por: Alkhawajah, Mona, et al.
Publicado: (2011)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2023)

A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
por: Pisani, Anna Isabella, et al.
Publicado: (2021)

Serum Levels of Anti-Myelin Antibodies in Relapsing-Remitting Multiple Sclerosis Patients during Different Phases of Disease Activity and Immunomodulatory Therapy
por: Angelucci, Francesco, et al.
Publicado: (2005)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
por: Capone, Fioravante, et al.
Publicado: (2021)

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
por: Imani, Ali, et al.
Publicado: (2012)

Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Abdel-mannan, Omar A., et al.
Publicado: (2021)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties
por: Marrone, Giuseppe, et al.
Publicado: (2023)

Gallbladder perforation without cholecystitis in a patient awaiting liver transplantation: a peculiar case report of anaemia in cirrhosis
por: Biolato, Marco, et al.
Publicado: (2019)

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis
por: Koudriavtseva, Tatiana, et al.
Publicado: (2020)

Metabolic Insights into Iron Deposition in Relapsing-Remitting Multiple Sclerosis via 7 T Magnetic Resonance Spectroscopic Imaging
por: Lipka, Alexandra, et al.
Publicado: (2023)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients
por: Bertolotto, Antonio, et al.
Publicado: (2020)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Defective structural RNA processing in relapsing-remitting multiple sclerosis
por: Spurlock, Charles F, et al.
Publicado: (2015)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Sexual dysfunction in female patients with relapsing‐remitting multiple sclerosis
por: Bartnik, Pawel, et al.
Publicado: (2017)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: Lesage, E., et al.
Publicado: (2010)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Circadian Activity Rhythm in Early Relapsing–Remitting Multiple Sclerosis
por: Tonetti, Lorenzo, et al.
Publicado: (2019)

Systematic review of prediction models in relapsing remitting multiple sclerosis
por: Brown, Fraser S., et al.
Publicado: (2020)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k5ibhjtp30iqvr1ss5h6ja233b